Navigation Links
Fragile X Syndrome Corrected in Mice
Date:12/19/2007

Discovery may lead to treatments for the genetic disease, a leading cause of mental retardation ,,,,

WEDNESDAY, Dec. 19 (HealthDay News) -- By targeting one gene, scientists have been able to correct many of the abnormalities associated with fragile X syndrome, the most common inherited form of childhood retardation.

Fragile X syndrome is caused by loss of the gene for "fragile X mental retardation protein" (FMRP). It affects about 100,000 people in the United States and is also a leading known genetic cause of autism.

There is currently no treatment or therapy for fragile X syndrome. Symptoms include mental retardation, epilepsy, and abnormal body growth.

"Fragile X is caused by the silencing of a single gene encoding FMRP," said lead researcher Mark F. Bear, director of the Picower Institute and the Picower professor of neuroscience at MIT in Cambridge, Mass. "FMRP regulates protein synthesis in the brain," he explained.

But the findings suggest that a drug could correct many of the symptoms of the disease.

"You are not doomed with the absence of this gene," Bear said. "If we could even come in late and correct it, there is a good chance that we could alter brain development and improve the symptoms," Bear said.

The report is published in the Dec. 20 issue of Neuron.

In the study, Bear's team used mice engineered to lack the FMRP gene. This caused the animals to develop many of the characteristics of human fragile X syndrome.

The lack of FMRP acts as a brake on protein synthesis in specific areas of brain circuitry. According to Bear's group, loss of this genetic "brake" allows another protein driving the syndrome -- called metabotropic glutamate receptor 5 (mGluR5) -- to get out of control.

So, a lack of functioning FMRP brings about runaway protein synthesis, Bear noted. But, "if we could dial back activity at the mGluR5 receptor, we might be able to bring the system back into balance and correct fragile X syndrome," he theorized.

Investigating that notion, Bear's team created mutant mice that lacked both the FMRP gene and had a 50 percent reduction in their production of mGluR5. They reduced rather than eliminated the activity of mGluR5, so that they could mimic what might happen if a drug treatment for fragile X was used in humans.

The mouse tests showed that the reduction in the mGluR5 gene could stop many of the abnormalities caused by the absence of FMRP. The double-mutant mice showed an improvement in their brain structure and function, in their brains' ability to make key proteins, as well as in memory and body growth.

Animals without the FMRP gene did produce an overgrowth of the spinal neurons called dendritic spines. However, the accompanying 50 percent reduction in mGluR5 allowed mice to maintain normal spine density.

In addition, the double mutant mice had substantial reductions in epileptic seizures, the researchers found.

Based on these results, human trials focused on mGluR5 should begin next year, Bear said. "I am cautiously optimistic that we will be able to correct some of the symptoms of the disease," he said.

One expert believes that mGluR5 could be a powerful target for correcting fragile X syndrome.

"This is a very important paper that demonstrates a remarkable rescue of fragile X features when the knockout mouse is crossed with a mGluR5-deficient mouse," said Dr. Randi Hagerman, a professor of pediatrics and medical director of the M.I.N.D. Institute at the University of California, Davis.

This is "wonderful" support for the therapeutic use of drugs known as mGluR5 antagonists in the treatment of fragile X syndrome, Hagerman said.

"Although there was good evidence for this treatment in the trial of mGluR5 antagonists in the knockout mouse [lacking FMRP] and other animal models of fragile X, this genetic evidence further supports treatment trials and suggests that earlier use of these agents may be very beneficial, since the genetic model corrects this problem throughout development," Hagerman said.

"We are initiating mGluR5 antagonist trials in humans now, and we are excited to see the benefit in adults with fragile X," Hagerman said. "This work is ushering in a new age of targeted treatments for fragile X syndrome."

Another expert agreed.

"Needless to say, we are very excited about this publication, which has actually been in the works for a long time," said Dr. Michael Tranfaglia, the medical director of the FRAXA Research Foundation, which is focused on fragile X. "The genetic rescue of most of the major features of fragile X syndrome by decreasing the expression of mGluR5 is an elegant and powerful demonstration of the 'mGluR5' theory.'"

In this case, the breakthrough finding has led to the conclusion that fragile X syndrome is primarily the result of excessive activity in a single cellular receptor pathway, Tranfaglia said.

Drugs are currently in development that can block this receptor, Tranfaglia said. "We believe these drugs have enormous potential for the treatment of fragile X and related developmental disorders, including many cases of autism," he said.

More information

For more about fragile X syndrome, visit the Fragile X Research Foundation.



SOURCES: Mark F. Bear, Ph.D., director, Picower Institute, and Picower professor of neuroscience, MIT, Cambridge, Mass.; Michael Tranfaglia, M.D., medical director, FRAXA Research Foundation, Newburyport, Mass; Randi Hagerman, M.D., professor, pediatrics, and medical director, M.I.N.D. Institute, University of California, Davis; Dec. 20, 2007, Neuron


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. $21.8 Million NIH Grant for Fragile X Research
2. Stem cell research produces a key discovery for Fragile X Syndrome
3. Brain Defect Helps Drive Fragile X Syndrome
4. Fragile X Foundations Sign Merger Agreement
5. Diabetes appears to increase risk of death for patients with acute coronary syndromes
6. Eye-staining technique offers early detection for dry eye syndrome
7. Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome
8. Treating depression may improve recovery of heart rate variability following coronary syndromes
9. Metabolic syndrome heightens risk for development of uric-acid kidney stones
10. Stomach Virus a Culprit in Chronic Fatigue Syndrome
11. Chronic fatigue syndrome linked to stomach virus
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fragile X Syndrome Corrected in Mice 
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: